VERV - Verve Therapeutics, Inc.
IEX Last Trade
6.055
0.125 2.064%
Share volume: 33,583
Last Updated: Fri 27 Dec 2024 06:30:29 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$5.93
0.13
2.11%
Fundamental analysis
13%
Profitability
8%
Dept financing
6%
Liquidity
75%
Performance
5%
Performance
5 Days
-2.20%
1 Month
8.66%
3 Months
16.33%
6 Months
14.94%
1 Year
-61.04%
2 Year
-67.68%
Key data
Stock price
$6.06
DAY RANGE
$5.92 - $6.52
52 WEEK RANGE
$4.55 - $19.34
52 WEEK CHANGE
-$61.40
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Sekar Kathiresan
Region: US
Website: vervetx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vervetx.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Verve Therapeutics, Inc. engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver.
Recent news